Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical CareSeptember 06, 2024 Eversheds Sutherland has advised Edwards Lifesciences on the US$4.2bn sale of its Critical Care product group to Becton, Dickinson and Company (BD). Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The Critical Care product group is an industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Key contacts
Lee Harris Partner United Kingdom Antony Walsh Partner United Kingdom Barri Mendelsohn Partner United Kingdom Rachel Cooper Partner United Kingdom Edward M. Tompkin-Haag Partner United Kingdom Kelly Holmes Partner United Kingdom Philip Crosbie Partner United Kingdom Christopher Murray Partner United Kingdom Latest News
Latest Eventsdeal alerts September 25, 2026 Eversheds Sutherland is advising Goodyear on the sale of its long-standing ... client news September 21, 2026 All change: Eversheds Sutherland advises DfT on Chiltern Railways transitio... deal alerts September 07, 2026 Eversheds Sutherland advises Finkemeier Holding on capital increase in egge... firm news August 26, 2026 |